Fondo Strategico backs Kedrion Biopharma

The investment is equally split between ordinary shares and convertible loans and will underpin the international expansion of the firm. Acquisitive growth is also planned, with a target company already identified.

The investment is the second announced by Fondo Strategico, following a €500m capital injection in Metroweb.

Company
Founded in 2001 and based in Milan, Kedrion Biopharma develops, produces and distributes plasma pharmaceuticals for treatment of clotting, immunodeficiency, autoimmune and infectious diseases.

The firm operates primarily in Italy but also has a presence in the US.

Last year, the company reported a €324m turnover and €75m EBITDA. On average, revenues grew annually by 11.9% and EBITDA by 18.2% between 2005 and 2010.

Kedrion employs around 1,400 members of staff – 800 of which are based in Italy – across four sites.

People
Giovanni Gorno Tempini is chairman of Fondo Strategico, while Roberto Marsella is an investment director.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Expansion
• Now researching
• Italy
• Fondo Strategico Italiano